InvestorsHub Logo
Followers 89
Posts 17610
Boards Moderated 0
Alias Born 09/06/2006

Re: forumreader35 post# 80789

Wednesday, 10/26/2016 12:09:02 PM

Wednesday, October 26, 2016 12:09:02 PM

Post# of 711200

Check out front page of fiercebiotech today for Merck article
First paragraph:


And check out the later paragraph:

The pharma is leaving no stone unturned in its Keytruda combo efforts; it has more than 200 ongoing combination studies in more than 30 different tumor types. The PD-1 inhibitor is in more than 30 registration studies in 22 different malignancies with in excess of 360 clinical studies in total as a monotherapy and combo.


200 combo trials already running with Merck. And many hundreds more combos with the other PD(L)-1 agents.

It's a race. That is why they are throwing literally billions at these trials.

And the DCVax combo trials? Crickets.

Waiting on what?

Money? Well in that case buying Sawston to fix it up and lease it out was kind of a bad move.

Perhaps the FDA partial hold issue? Who knows, as we are in the dark. I am sure that longs here are correct though that an FDA partial hold is not an issue. Yeah.

All that is known is that the combo trials are not starting, and do not even have any announced firm plans to start.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News